聚基酸合成酶13 (Pks13) 抑制:一种新型抗结核药物类别的潜在目标
Sonia Khola1, Sachin Kumar1, Neeru Bhanwala1
1Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research-Raebareli, Uttar Pradesh, 226002, India.
Current topics in medicinal chemistry
|September 19, 2024
概括
针对Pks13酶的新药对于对抗多药耐药结核病 (MDR-TB) 至关重要. 几种化学化合物在抑制Pks13方面表现有前途,为这种全球健康威胁提供了潜在的新疗法.
科学领域:
- 微生物学 微生物学
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
背景情况:
- 结核病 (TB) 仍然是一个重大的全球健康威胁,由多药耐药 (MDR) 和广泛耐药 (XDR) 菌株加剧.
- 现有的结核病药物具有局限性,包括严重的副作用和对抗耐药菌株的有效性降低,需要新的治疗策略.
- 对于真菌细菌中酸生物合成至关重要的Pks13酶,代表了开发新抗结核病药物的有希望的药物标.
研究的目的:
- 通过向Pks13酶来识别和评估具有抗结核活性的新型化学实体.
- 探索Pks13的潜力,作为开发抗耐药结核病新药的关键目标.
- 为了研究抑制Pks13活性的特定联结体类.
主要方法:
- 使用Pks13作为目标的酶抑制测定.
- 选化学实体,包括佐,烯,库梅斯坦,N-英多尔和β-乳.
- 鉴定Pks13抑制剂的抗结核性质的评估.
主要成果:
- 证实Pks13是抗结核药物开发的可行目标.
- 几种类型的化合物,包括佐,烯,库梅斯坦,N-英多尔和β-乳,对Pks13表现出抑制作用.
- 这些Pks13抑制剂显示出潜在的抗结核性质.
结论:
- 向Pks13酶是开发针对耐药结核病的新疗法的一个有希望的策略.
- 已识别的配体代表了潜在的化合物,可用于进一步开发新的抗结核药物.
- 对Pks13抑制剂的进一步研究可能会导致针对多药耐药和广泛耐药结核病的有效疗法.
更多相关视频
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
7.8K
09:57Visualization of the Charcoal Agar Resazurin Assay for Semi-quantitative, Medium-throughput Enumeration of Mycobacteria
Published on: December 14, 2016
10.4K
相关概念视频
01:28Pulmonary Tuberculosis V
172
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
172
01:19Allosteric Proteins-ATCase
5.7K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.7K
01:26Targets for Drug Action: Overview
6.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.1K